Podcasts Culture Overprescribed Low Diversity in Clinical Trial Patients & Why That's a Problem

Low Diversity in Clinical Trial Patients & Why That's a Problem

Published: May 18, 2018, 10:50 a.m.

The FDA keeps approving drugs that have been tested on groups of patients that are not really diverse and this is a problem. Listen in and find out why. 

 

Show note links:

Drug Trials Snapshots page from the FDA's website where you can learn about what these snapshots are about, how to use them, snapshot limitations and sort the table of snapshots to find the newest drugs that made the list in 2018 (so far)

2017 Drug Trials Snapshots Summary Report 

2018 new drug FDA approvals mentioned in this episode:

Akynzeo

Crysvita

Tavalisse

Ilumya

Trogarzo

Erleada

Symdeko

Biktarvy

Lutathera

 

*****BONUS links:

USA Today article on the Tuskegee Syphilis Study 45 Years Later

The FDA's press announcement (released March 2018) on the new drug approval for Trogarzo which was approved based on clinical data results of 40 patients via Fast Track, Priority Review, Breakthrough Therapy designation and Orphan Drug status

Join our private Facebook group - Consumers Unite!